Pharmaceutical stocks have been a safe harbor in a choppy stock market, and for good reason.

Twitter is proving that smaller may be better, even in social media, as purging users makes Twitter’s advertising business more healthy.

The U.S. Federal Reserve’s interest-rate increases are roiling the emerging-market currencies in which Anheuser-Busch InBev makes roughly two-thirds of its sales.

The company’s 15% growth is a significant number for a business generating more than $200 billion in annual sales, but it is not the kind of growth its investors have been banking on.

Shares in Samsung and SK Hynix have suffered despite both companies reporting record earnings.

The diverging fates of Barclays and Deutsche Bank are connected by the amount of cheap funding they can offer clients.